PER 1.23% 8.0¢ percheron therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5

  1. 1,066 Posts.
    lightbulb Created with Sketch. 498
    Crucially (re combo study we're all waiting on):

    Functional analysis results are due imminently with the cellular analysis to follow next month. Any applicable patent filings would bemade ahead of disclosure of the results.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.